3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
177
Neoplasm Metastasis
19
Breast Neoplasms
19
Prostatic Neoplasms, Castration-Resistant
17
Neoplasms
17
Metastatic Castration Resistant Prostate Cancer
8
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Triple Negative Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Castration-resistant Prostate Cancer
4
Carcinoma, Hepatocellular
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Prostate Adenocarcinoma
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
mCRPC
2
Uterine Cervical Neoplasms
2
Recurrence
2
Prostatic Diseases
2
Metastatic Hormone Sensitive Prostate Cancer
2
Interventions
Levetiracetam
6
Cannabidiol
4
perampanel
2
Standard of Care
2
Everolimus
2
enzalutamide
1
Vigabatrin
1
Tranexamic Acid
1
Temozolomide
1
Sodium Chloride
1
Saline Solution
1
Pregabalin
1
Medical Marijuana
1
Magnesium Sulfate
1
Drug Therapy
1
Curcumin
1
Cholecalciferol
1
Aspirin
1
Anticonvulsants
1
Anastrozole
1
Airway Extubation
1
2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Seizures
×
enzalutamide
×
Clear all
NCT01977651
2024-12-06
UPWARD
Astellas Pharma Inc
Phase 4
Completed
424 enrolled
10 charts